Log In
BCIQ
Print this Print this
 

EBI-031

  Manage Alerts
Collapse Summary General Information
Company Eleven Biotherapeutics Inc.
Description mAb that binds IL-6 and inhibits IL-6 signaling
Molecular Target Interleukin-6 (IL-6)
Mechanism of ActionInterleukin-6 (IL-6) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetic macular edema (DME)
Indication DetailsTreat diabetic macular edema (DME)
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$270.0M

$7.5M

$262.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/13/2016

$270.0M

$7.5M

$262.5M

Get a free BioCentury trial today